GLUE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

15.51M

-74.43%

-0.317

-217.29%

6.10M

-92.82%

-0.465

-181.58%

6.10M

-73.7%

-0.480

+220%

Estimates Revision

The market is revising Downward the revenue expectations for Monte Rosa Therapeutics, Inc. (GLUE) for FY2025, with the revenue forecasts being adjusted by -3.6% over the past three months. During the same period, the stock price has changed by 141.83%.

Revenue Estimates for FY2025

Revise Downward

-3.6%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+475.7%

In Past 3 Month

Stock Price

Go Up

+141.83%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

18.00

High

20.00

Current: 0.000

Low

16.00

Averages

18.00

High

20.00

Wells Fargo

Equal Weight -> Overweight

upgrade

$22

2025-12-16

Reason

Wells Fargo

Price Target

$22

2025-12-16

upgrade

Equal Weight -> Overweight

Reason

Wells Fargo upgraded Monte Rosa Therapeutics (GLUE) to Overweight from Equal Weight with a $22 price target. The firm cites the company's catalyst path in 2026 for the upgrade. Wells sees upside from MRT-8102's Phase 1 update in the first half of 2026 and likely disclosure of Novartis' (NVS) plans for MRT-6160. The MRT-8102 Phase 1 update should be "de-risking," the analyst tells investors in a research note.

Wedbush

Robert Driscoll

Buy

Maintains

$15 → $17

2025-03-21

Reason

Wedbush

Robert Driscoll

Price Target

$15 → $17

2025-03-21

Maintains

Buy

Reason

Wedbush raised the firm's price target on Monte Rosa Therapeutics to $17 from $15 and keeps an Outperform rating on the shares after the company reported Q4 financials and provided clinical updates for its VAV1 and MRT-2359 programs in immunology and oncology, respectively. Monte Rosa shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of over 90% and substantial ablation of T and B cell function shown by reduction in cytokine release from T and B cells following ex vivo stimulation, the firm notes. Taken together, Wedbush sees these data as providing robust support for further evaluation of the molecule in Phase 2 studies in immune mediated diseases, including autoimmune indications such as colitis and rheumatoid arthritis.

Wells Fargo

Derek Archila

Hold

Maintains

$11 → $10

2025-03-21

Reason

Wells Fargo

Derek Archila

Price Target

$11 → $10

2025-03-21

Maintains

Hold

Reason

Wells Fargo analyst Derek Archila lowered the firm's price target on Monte Rosa Therapeutics to $10 from $11 and keeps an Equal Weight rating on the shares. The firm likes the progress on MRT-6160 and believes it increases the odds of future milestones and royalties. That said, Monte Rosa Therapeutics' programs remain early and with limited catalysts in the near term, Wells expects shares to be range bound.

Valuation Metrics

The current forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE.O) is -8.89, compared to its 5-year average forward P/E of -4.79. For a more detailed relative valuation and DCF analysis to assess Monte Rosa Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.79

Current PE

-8.89

Overvalued PE

-1.29

Undervalued PE

-8.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.21

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.52

Undervalued EV/EBITDA

-5.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.31

Current PS

29.49

Overvalued PS

23.36

Undervalued PS

-2.74

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GLUE News & Events

Events Timeline

No data

News

8.5

01-09Yahoo Finance

PinnedMonte Rosa Prices Public Offering of 11.125M Shares at $24 Each, Raising $300M

9.0

01-09NASDAQ.COM

ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis

8.5

01-09Yahoo Finance

Monte Rosa Therapeutics Prices $11.1 Million Public Offering

People Also Watch

Frequently Asked Questions

What is Monte Rosa Therapeutics Inc (GLUE) stock price today?

The current price of GLUE is 24.28 USD — it has decreased -4.07 % in the last trading day.

What is Monte Rosa Therapeutics Inc (GLUE)'s business?

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

What is the price predicton of GLUE Stock?

What is Monte Rosa Therapeutics Inc (GLUE)'s revenue for the last quarter?

Monte Rosa Therapeutics Inc revenue for the last quarter amounts to 12.77M USD, increased 38.54 % YoY.

What is Monte Rosa Therapeutics Inc (GLUE)'s earnings per share (EPS) for the last quarter?

Monte Rosa Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, increased 13.79 % YoY.

What changes have occurred in the market's expectations for Monte Rosa Therapeutics Inc (GLUE)'s fundamentals?

How many employees does Monte Rosa Therapeutics Inc (GLUE). have?

Monte Rosa Therapeutics Inc (GLUE) has 134 emplpoyees as of January 10 2026.

What is Monte Rosa Therapeutics Inc (GLUE) market cap?

Today GLUE has the market capitalization of 1.58B USD.